2022 World Conference on Lung Cancer (ePosters)-EP14.01-006. CeLEBrATE: Phase II trial of CarbopLatin, Etoposide, Bevacizumab and Atezolizumab in Patients with exTEnsive-Stage SCLC-GOIRC-01-2019

EP14.01-006. CeLEBrATE: Phase II trial of CarbopLatin, Etoposide, Bevacizumab and Atezolizumab in Patients with exTEnsive-Stage SCLC-GOIRC-01-2019

Back to course

Pdf Summary

The CELEBrATE trial is a phase II study investigating the combination of carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage small-cell lung cancer (ES-SCLC). ES-SCLC is an aggressive neuroendocrine tumor of the lung that accounts for a significant proportion of lung cancers. The standard treatment for this disease has been platinum-etoposide chemotherapy, but the addition of PD-L1 inhibition with atezolizumab has shown improved survival rates in phase III trials.<br /><br />However, the prognosis for ES-SCLC remains poor, and new treatment strategies are urgently needed. The Vascular Endothelial Growth Factor (VEGF) has been shown to sustain angiogenesis and have immunosuppressive effects. Previous trials have demonstrated the safety and activity of adding bevacizumab to platinum doublet chemotherapy in patients with ES-SCLC.<br /><br />The CELEBrATE trial aims to assess the efficacy and safety of the combination of bevacizumab, atezolizumab, carboplatin, and etoposide in treatment-naive patients with ES-SCLC. Patients received the combination therapy in an induction phase for 4-6 courses, followed by a maintenance phase for up to 18 total cycles. Eligible patients with asymptomatic brain metastases were included in the trial.<br /><br />The primary objective of the study is to evaluate the 1-year cumulative survival rate, with secondary objectives including safety and activity. Overall survival rate at 1 year, overall response rate, progression-free survival, and toxicity are among the primary and secondary endpoints of the trial.<br /><br />The study is an investigator-initiated multicenter trial, and a total of 54 patients were enrolled. The results are expected in the second quarter of 2023. The pre-clinical rationale for the combination therapy lies in the role of angiogenesis in the growth and development of metastases in small-cell lung cancer.<br /><br />The trial has the potential to provide insights into the efficacy and safety of combining bevacizumab, atezolizumab, carboplatin, and etoposide for the treatment of ES-SCLC, offering new treatment options for this aggressive form of lung cancer.

Asset Subtitle

Giuseppe Lamberti

Meta Tag

Speaker Giuseppe Lamberti

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

Keywords

CELEBrATE trial

carboplatin

etoposide

bevacizumab

atezolizumab

ES-SCLC

neuroendocrine tumor

platinum-etoposide chemotherapy

angiogenesis

new treatment options